linjc16/ctgov huggingface dataset:
Oral and Perioral Herpes Simplex Virus Infection Type I in a Five-month-old Infant: A Case Report

Study Overview
=================
Brief Summary
-----------------
A five-month-old healthy girl who presented with painful herpetic gingivostomatitis and perioral vesicles.

Detailed Description
-----------------
The investigators present the case of a five-month-old healthy girl who presented with painful herpetic gingivostomatitis and perioral vesicles. The investigators discuss the pathophysiology of primary herpes simplex virus infection and the effect of maternal antibodies on the infant's immune system. In addition, the investigators explain the diagnosis, management, and prognosis of herpes simplex virus infection in young infants.

Official Title
-----------------
Oral and Perioral Herpes Simplex Virus Infection Type I in a Five-month-old Infant: A Case Report

Conditions
-----------------
Herpes Simplex Virus Infection

Intervention / Treatment
-----------------
* Diagnostic Test: Diagnosis and treatment of the case


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Five-months-old infants or younger Exclusion Criteria: Six-months-old infants or older
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: Diagnosis and treatment of the case|The infant was transferred to a hospital for better management of her infection. She was immediately started on intravenous acyclovir (20 mg/kg/6 h/5 d) while acetaminophen suppositories (80 mg/8 h/5 d) were given to lower her body temperature. In addition, other palliative drugs, such as diphenhydramine syrup (12.5 mg/5 mL, 2.5 mL orally) once-a-night for five days, were given to ease the effort of drinking and to aid in achieving good sleep. Upon completion of five days of therapy, the patient showed complete recovery and was subsequently discharged from the hospital free from symptoms.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Health condition | Number of tests were performed and different drugs were administered | one week | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Herpetic gingivostomatitis, Herpes simplex virus, Perioral lesions, Infants, Case report, Herpes simplex virus type 1, Oral lesions
Effect of Intranasal Insulin on Postoperative Cognitive Dysfunction

Study Overview
=================
Brief Summary
-----------------
Our study is designed to evaluate the effect of intranasal insulin on postoperative cognitive dysfunction. Primary outcome: 1. The occurrence of cognitive dysfunction at approximately 7 days after surgery. Secondary outcome: 1. Incidence of any side effect.

Official Title
-----------------
Effect of Intranasal Insulin on Postoperative Cognitive Dysfunction in Middle Aged Patients Undergoing Non Cadiac Surgery.

Conditions
-----------------
Middle Aged Patients

Intervention / Treatment
-----------------
* Drug: Intranasal insulin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 40 - 60 years. Both gender. Patients will be scheduled for elective major abdominal, thoracic, orthopedic, open gynecological, open urological, spine, otolaryngological surgeries under general anesthesia with expected hospital stay >4 days. Exclusion Criteria: 1. Drug allergy. 2. Patients with major psychiatric disease. 3. Patients receive major tranquillizers and antidepressant. 4. Those undergoing neurosurgery or cardiac surgery. 5. Those unable or unwilling to abide by the study procedure 6. Those who could not follow procedure or who had poor comprehension of dutch language. 7. Those with sever visual and auditory disorder / handicaps.

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Control group.<br> | |
| Surgical group Received intranasal insulin.<br> | Drug: Intranasal insulin<br>* Surgical group Received intranasal insulin, the second group surgical Received placebo and the third group is non surgical do not receive anything.<br>|
| Surgical group Received placebo.<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cognitive dysfunction | The occurrence of cognitive dysfunction at approximately 7 days after surgery. | 7 days |
Gut Health Response to Dietary Fiber

Study Overview
=================
Brief Summary
-----------------
Dietary fiber is known to influence bowel function. The investigators hypothesize that the addition of a mixture of fibers to liquid diets will improve bowel function as measured by stool weight.

Detailed Description
-----------------
Liquid diets are the sole source of nutrition for many patients. Consumption of liquid diets is linked to lower stool weight. The objective of this study is to feed liquid diets, with and without added fiber, to healthy human subjects to determine if mixed fiber sources can normalize stool weight. Secondary objectives of the study include measurement of gut microbiota and stool chemistry with fiber addition.

Official Title
-----------------
Gut Health Response to a New Fiber Blend

Conditions
-----------------
Dietary Fiber

Intervention / Treatment
-----------------
* Dietary Supplement: dietary fiber


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1.Weight BMI between 23 - 29 having obtained his/her informed consent willing and able to exclusively consume enteral diets for two 14 day periods willing and able to collect stool samples as instructed Exclusion Criteria: any disease use of medication except for contraceptive medication and certain OTC medications not affecting laxation smoking excessive exercise (> 2 hours per week) consumption of more than 20 grams of dietary fiber daily pregnancy or lactation use of laxatives use of antibiotics in past 6 months use of pre or probiotics supplements in the past 2 months use of probiotic foods in the past month subjects who cannot be expected to comply with the study procedures currently participating or having participated in another clinical trial during the last 4 weeks prior to the beginning of this study known allergy or sensitivity to formula ingredients

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Dietary Supplement: dietary fiber|mixture of fiber sources added to liquid nutrition product|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Stool weight | 5 day fecal collection on last 5 days of 14 day feeding trial | 5 day collection | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| fecal microbiota | fecal sample on last day of feeding trial will be collected for microbiota analysis | day 14 of feeding trial | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
dietary fiber, enteral nutrition, laxation
Efficacy of Platelet Rich Plasma in Plantar Fasciitis

Study Overview
=================
Brief Summary
-----------------
Plantar fasciitis is a common pathology among podiatry moreover the healing time takes several months. The main aim of this study is to evaluate the efficacy of a injection of Platelet-Rich Plasma (PRP) versus corticosteroid injection.

Official Title
-----------------
Plantar Fasciitis Treatment: Double Blinded Randomized Control Study of the Efficacy of an Injection of Platelet Rich Plasma (PRP) Versus an Infiltration of Corticosteroids

Conditions
-----------------
Plantar Fascitis

Intervention / Treatment
-----------------
* Biological: Injection of autologous platelet rich plasma
* Drug: Injection of cortivazol : Altim®


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Plantar fasciitis Average VAS greater than or equal to 5/10 Resistance of medical reference treatment Exclusion Criteria: Other plantar lesion find on RMI Pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Arm A<br> | Biological: Injection of autologous platelet rich plasma<br> <br> |
| Active Comparator: Arm B<br> | Drug: Injection of cortivazol : Altim®<br>* Corticosteroids<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mean daily pain measured with a visual analog scale from 0 to 10 | Comparison of pain intensity, measured with a visual analog scale from 0 to 10 | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain intensity during the first steps of the day measured with a visual analog scale from 0 to 10 | Measured with a visual analog scale from 0 to 10 | 6 months | 
| Pain intensity on direct compression measured with a visual analog scale from 0 to 10 | Constant intensity of the compression, measured with a visual analog scale from 0 to 10 | 6 months | 
| Impairment of walking function | Foot function index | 6 months |
Psychobiology in Inflammatory Bowel Disease(IBD)

Study Overview
=================
Brief Summary
-----------------
Patients with ulcerous colitis and Crohn's disease, age 18-60, with a relapse within the last 18 months and an activity index ≥4, with a long time stress level ≥60 on the perceived stress questionnaire (PSQ) were randomized to a stress management intervention program or treatment as usual and followed up for 18 months.

Detailed Description
-----------------
The study includes distressed patients with ulcerous colitis and Crohn's disease with relapse or enduring activity last 18 months and an simple activity index ≥4, on stable medication last 4 weeks. All patients were followed by a gastroenterologist at baseline, 3, 6, 12 and 18 months follow up and a psychiatrist or clinical psychologist at 18 months. Half of the patients received additional psychosocial intervention (education, relaxation, supportive psychotherapy with stress management). Assessments include gastrointestinal assessments; blood tests; psychiatric evaluations and psychometric evaluations.

Official Title
-----------------
The Impact of Psychobiological Factors in Inflammatory Bowel Disease

Conditions
-----------------
Inflammatory Bowel Disease

Intervention / Treatment
-----------------
* Behavioral: Psychological behavioral intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Ulcerous colitis and Crohn's disease verified by histology and endoscope Relapse last 18 months or enduring activity Activity index≥4 PSQ≥60

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: Psychological behavioral intervention|3x3 hours group intervention followed by 6-9 hours individual psychotherapy based on cognitive behavioral methods|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Improvement in activity index. |  | 18 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reduction of inflammatory parameters. |  | 18 months | 
| Reduction in number of relapses. |  | 18 months | 
| Quality of life improvement |  | 18 months | 
| Psychobiological factors related to improvement |  | 18 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
IBD, psychological, stress management
North American Prodromal Synucleinopathy Consortium

Study Overview
=================
Brief Summary
-----------------
This study will enroll participants with idiopathic rapid eye movement (REM) sleep behavior disorder (RBD), for the purpose of preparing for a clinical trial of neuroprotective treatments against synucleinopathies.

Detailed Description
-----------------
REM sleep behavior disorder (RBD) is a rare disorder where people act out their dreams. People with RBD often, but not always, develop Parkinson's Disease, dementia with Lewy bodies, multiple system atrophy, or other neurodegenerative diseases of the synucleinopathy type. The North American Prodromal Synucleinopathy (NAPS) Consortium was formed with the purpose of enrolling participants with RBD, in anticipation of a future clinical trial of a neuroprotective treatment against synucleinopathies. The NAPS Consortium will collect standardized clinical assessments, biofluids, and other data in order to develop biomarkers for synucleinopathies in the prodromal (presymptomatic) stage as well as a trial-ready registry of participants. Participants procedures will include a  2-hour clinical assessment (medical history and physical exam), questionnaires, blood draw, and (at select sites) optional lumbar puncture.

Official Title
-----------------
North American Prodromal Synucleinopathy Consortium

Conditions
-----------------
REM Sleep Behavior Disorder, Parkinson Disease, Lewy Body Disease, Dementia With Lewy Bodies, Multiple System Atrophy, REM Sleep Parasomnias

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Idiopathic REM sleep behavior disorder Exclusion Criteria: REM sleep behavior disorder secondary to another cause (ex: narcolepsy, dementia, Parkinson's Disease, etc) Other neurological disorder

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prodromal Synucleinopathy Rating Scale | Rating scale combining neurocognitive battery, motor, autonomic, olfaction, color vision functions. Global score range 0-3, with higher score indicating greater symptoms of synucleinopathy. | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
parasomnia, sleep, REM, rapid eye movement, parkinson, lewy body disease, dementia with lewy bodies, Multiple System Atrophy, synuclein, synucleinopathy
The Efficacy, Safety And Toleration Of CP-866,087 In Pre-Menopausal Women With Female Sexual Arousal Disorder.

Study Overview
=================
Brief Summary
-----------------
CP-866,087 is a non-hormonal compound, acting on the central nervous system, which has been shown in animal models to restore sexual function.

Official Title
-----------------
A Phase 2a Multi-Centre, Double Blind, Placebo Controlled Cross-Over Trial To Investigate The Efficacy, Safety And Toleration Of CP-866,087 In Pre-Menopausal Women Diagnosed With Female Sexual Arousal Disorder (FSAD).

Conditions
-----------------
Sexual Dysfunction, Physiological

Intervention / Treatment
-----------------
* Drug: CP-866,087
* Drug: CP-866,087
* Drug: CP-866,087
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: healthy pre-menopausal women primary female sexual arousal disorder causing distress on stable use of oral contraceptives Exclusion Criteria: any other significant disease causing Female Sexual Dysfunction including psychiatric disease subjects on drugs known to cause Female Sexual Dysfunction subjects who have given birth in the last 12 months or who are planning to become pregnant during the study

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1 mg<br> | Drug: CP-866,087<br>* Tablets for oral administration<br>|
| Experimental: 10 mg<br> | Drug: CP-866,087<br>* Tablets for oral administration<br>|
| Experimental: 3 mg<br> | Drug: CP-866,087<br>* Tablets for oral administration<br>|
| Placebo Comparator: Placebo<br> | Drug: Placebo<br>* Tablets for oral administration<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Diary events, including Satisfactory Sexual Experiences (SSEs) over 6 weeks. |  | 6 weeks | 
| Score in Abbreviated Sexual Function Questionnaire after 6 weeks of treatment. |  | 6 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Exit interview at end of study. Meaningful Benefit Question at end of study. |  | End of study | 
| Measure of Female Sexual Distress questionnaire after 6 weeks of treatment. |  | 6 weeks |
Safety and Efficacy of Restylane Vital for Skin Rejuvenation of Dorsal Hands

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the safety and efficacy of using Restylane Vital for skin rejuvenation of the dorsal hands. Assessment of improvement of skin structure will be done by a blinded evaluator.

Official Title
-----------------
A Randomised, Multi-centre, Evaluator-blinded, Split-hand, no Treatment-controlled Study to Evaluate the Safety and Efficacy of Restylane Vital for Skin Rejuvenation of the Dorsal Hands in Chinese Subjects

Conditions
-----------------
Dorsal Hands

Intervention / Treatment
-----------------
* Device: Restylane Vital


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Signed Informed Consent Chinese origin Subject willing and able to comply with the requirements of the study and agrees to adhere to the visit schedule and to be compliant to the study instructions Exclusion Criteria: Any previous non-permanent implant/filler in the hands Any mesotherapy or resurfacing procedure in the hands within 6 months prior to baseline Any previous hand surgery Any fibrosis or scarring or deformities on the hands Advanced photoaged/photodamaged skin

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Restylane Vital in both hands<br>Open group used to develop a proper use of injection technique for Restylane Vital | Device: Restylane Vital<br> <br> |
| Other: Restylane Vital and No treatment<br>Split-hand design: Restylane Vital in one hand and initially no treatment in the other hand | Device: Restylane Vital<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The Efficacy of Restylane Vital on Skin Structure Compared to no Treatment Using a Validated Scale. | Assessment of the severity of hand aging using a 5-point (ranging from 0-5) photo numeric rating scale (Hand Grading Scale), where higher scores mean a worse outcome. | 12 weeks |
Investigation on the Surgical Treatment Effect of Periprosthetic Femur Fracture After Hip Arthroplasty

Study Overview
=================
Brief Summary
-----------------
To Investigate the Surgical Treatment effect of Periprosthetic Femur Fracture After Hip Arthroplasty

Detailed Description
-----------------
In the study，155 patients from multiple center with periprosthetic femur fracture after hip arthroplasty are planned to be recruited. All the patients are treated surgically according to Vancouver classification，and their fracture union，pain in fracture site and lower extremity length are evaluated at 6 months and 1 year postoperatively．Also Harris scores are used to assess hip function at the 2 time points.

Official Title
-----------------
A Multi-center Study on Investigating the Surgical Treatment Effect of Periprosthetic Femur Fracture After Hip Arthroplasty

Conditions
-----------------
Periprosthetic Fractures

Intervention / Treatment
-----------------
* Procedure: surgically treated periprosthetic femur fracture


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with periprosthetic femur fracture after hip arthroplasty Exclusion Criteria: Severe complications after surgery

Ages Eligible for Study
-----------------
Minimum Age: 55 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| revision of periprosthetic fracture<br>patients with surgically treated periprosthetic femur fracture | Procedure: surgically treated periprosthetic femur fracture<br>* patients with surgically treated periprosthetic femur fracture<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| fracture union | fracture union from X-ray | 1 year after surgery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| hip function | Harris Hip Score | 1 year after surgery | 
| pain in fracture site | VAS score | 1 year after surgery | 
| lower extremity length | The lengths of injured lower extremity | 1 year after surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Periprosthetic Fractures, Arthroplasty, Surgical procedures